Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 29 Growth opportunities supported by strong global presence in both sales and manufacturing FTEs in sales regions¹ USA: ~5,100 West Lebanon, NH, USA (~120)² ~2,800 Biopharmaceutical API production Europe: International Operations: ~5,400 Pacific: ~1,500 Region China: ~2,900 Total non-HQ/manufacturing FTES: 17,700¹ Global manufacturing setup Denmark (~9,700 FTEs) Diabetes and biopharmaceutical API production Filling Moulding and assembly Packaging Kaluga, Russia (~230 FTEs) Filling Assembly Packaging Clayton, NC, USA (~820 FTEs) Diabetes API production Filling Assembly Packaging of above Montes Claros, Brazil (~930 FTEs) Filling Assembly Packaging Koriyama, Japan (~70 FTEs) Packaging Chartres, France (~1,100 FTEs) Filling Assembly Packaging Tianjin, China (~1,000 FTEs) Filling Moulding and Assembly Packaging 1 FTEs represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of October 2016 2 New Hampshire facility is currently under establishment changing diabetes novo nordisk

View entire presentation